Annals of Hematology

, Volume 87, Issue 9, pp 763–765 | Cite as

JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia

  • María J. Moreno
  • María L. Lozano
  • V. Roldán
  • B. Bellosillo
  • N. García-Barberá
  • J. Rivera
  • L. Navarro-Núñez
  • C. Besses
  • V. Vicente
  • C. Martínez
Letter to the Editor

References

  1. 1.
    Campbell PJ, Green AR (2006) The myeloproliferative disorders. N. Engl J Med 355:2652–2666CrossRefGoogle Scholar
  2. 2.
    Tefferi A, Elliott MA (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Haemost 33:313–320CrossRefGoogle Scholar
  3. 3.
    Elliott MA, Tefferi A (2005) Thrombosis and Haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 128:275–290PubMedCrossRefGoogle Scholar
  4. 4.
    Griesshammer M (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32:372–380PubMedCrossRefGoogle Scholar
  5. 5.
    Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109:2310–2313PubMedCrossRefGoogle Scholar
  6. 6.
    Afshar-Kharghan V, Lopez JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A (2004) Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 15:21–24PubMedCrossRefGoogle Scholar
  7. 7.
    Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F (2002) Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 71:1–6PubMedCrossRefGoogle Scholar
  8. 8.
    Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C (2006) The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 132:244–245PubMedCrossRefGoogle Scholar
  9. 9.
    Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T (2007) Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840–846PubMedCrossRefGoogle Scholar
  10. 10.
    Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E (1999) Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13:150–154PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • María J. Moreno
    • 1
  • María L. Lozano
    • 1
  • V. Roldán
    • 1
  • B. Bellosillo
    • 2
  • N. García-Barberá
    • 1
  • J. Rivera
    • 1
  • L. Navarro-Núñez
    • 1
  • C. Besses
    • 2
  • V. Vicente
    • 1
  • C. Martínez
    • 1
  1. 1.University of Murcia, Centro Regional de HemodonaciónMurciaSpain
  2. 2.Hospital del MarIMASBarcelonaSpain

Personalised recommendations